Arcutis Biotherapeutics
ARQT
94 hedge funds and large institutions have $1.35B invested in Arcutis Biotherapeutics in 2021 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 44 increasing their positions, 17 reducing their positions, and 6 closing their positions.
963% more call options, than puts
Call options by funds: $3.69M | Put options by funds: $347K
267% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 6
159% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 17
21% more funds holding
Funds holding: 78 → 94 (+16)
18% more capital invested
Capital invested by funds: $1.15B → $1.35B (+$202M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.4% less ownership
Funds ownership: 93.91% → 93.51% (-0.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$40.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.1M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$27.4M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$24.4M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$20.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$32.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.6M |
| 3 |
Goldman Sachs
New York
|
-$6.35M |
| 4 |
Millennium Management
New York
|
-$4.53M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$3.83M |
ARQT Hedge Fund Activity: Q1 2021 in Review
94 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q1 2021, worth a combined $1.35B — up 18% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ARQT positions and 6 closed out — a net gain of 16 holders — while 44 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock, adding an estimated $40.8M. The largest seller was RA Capital Management, exiting entirely with an estimated $32.8M sold.
- 94 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q1 2021, up from 78 in Q4 2020.
- Funds reported $1.35B of Arcutis Biotherapeutics stock for Q1 2021, up 18% quarter-over-quarter.
- 22 funds opened new Arcutis Biotherapeutics positions in Q1 2021 and 6 closed out, a net change of +16 holders.
- The largest Arcutis Biotherapeutics buyer in Q1 2021 was BlackRock, an estimated $40.8M added.
- The largest Arcutis Biotherapeutics seller in Q1 2021 was RA Capital Management, an estimated $32.8M sold.
Based on aggregated 13F filings for Q1 2021.